|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study.
|
31742767 |
2020 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Single-agent PSMA-targeted radioligand therapy (PRLT) with the alpha-emitter <sup>225</sup>Ac showed promise against mCRPC but may cause severe and/or persistent xerostomia, which may substantially impair patients' quality-of-life.
|
31758224 |
2020 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to calculate absorbed doses for critical organs and tumor lesions for [<sup>177</sup>Lu]Lu-RM2 therapy administered in a group of metastatic castration-resistant prostate cancer (mCRPC) patients who had insufficient PSMA expression or showed lower PSMA accumulation after previous cycles of [<sup>177</sup>Lu]Lu-PSMA-617 therapy.
|
31482426 |
2020 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
|
31789908 |
2020 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here, we aimed to estimate the results of PSMA-RLT in terms of response, progression-free survival (PFS), and overall survival (OS) in patients receiving a highly standardized treatment regimen due to mCRPC.
|
31781834 |
2020 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lutetium-177 (Lu)-labeled prostate-specific membrane antigen radioligand therapy (Lu-PRLT) has demonstrated encouraging efficacy in mCRPC.
|
31162261 |
2020 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
PRLT with LuPSMA and AcPSMA is a well-tolerated and effective treatment modality for mCRPC.
|
31644433 |
2020 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
PATIENT SUMMARY: We analyzed the treatment outcome and toxicity of prostate-specific membrane antigen-targeted radioligand therapy in patients with metastatic castration-resistant prostate cancer.
|
30473431 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate-specific membrane antigen (PSMA) is an attractive target for radionuclide therapy of metastatic castration-resistant prostate cancer (mCRPC).
|
31831560 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent years have seen the start of treatment of metastatic castration-resistant prostate cancer with prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (PRLT), especially <sup>177</sup>Lu-PSMA-617.
|
30850503 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Oligoarginine sequences conjugated to a short cancer-targeting peptide (CTP) selective for the prostate-specific membrane antigen (PSMA) receptor was developed for selective small interfering RNA (siRNA) delivery to a human metastatic/castration-resistant prostate cancer (PCa) cell line, which expresses PSMA on the surface.
|
31739211 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
With recent developments in PSMA-targeted radiopharmaceuticals, PSMA RLT agents are now under investigation for the treatment of mCRPC.
|
31353876 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
177Lu-PSMA and 177Lu-DOTATATE Therapy in a Patient With Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Differentiation.
|
31693627 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this first-in-man dose-escalation study, PSMA ADC was administered by intravenous infusion every three weeks to subjects with progressive metastatic castration-resistant prostate cancer (mCRPC) who were previously treated with docetaxel chemotherapy.
|
30663074 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Excellent Response to Lower Dose of 177Lu-PSMA-617 in a Metastatic Castration-Resistant Prostate Cancer Patient With a Transplanted Kidney.
|
30829871 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>68</sup>Ga-PSMA PET/CT for monitoring response to <sup>177</sup>Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer.
|
30697649 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
First-in-human study of <sup>177</sup>Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
|
30090965 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>177</sup>Lu-PSMA-617 (Lu-PSMA) is an emerging therapy in men with metastatic castration-resistant prostate cancer.
|
30425003 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
To develop a prostate-specific membrane antigen (PSMA)-targeted radiotherapeutic for metastatic castration-resistant prostate cancer (mCRPC) with optimized efficacy and minimized toxicity employing the β-particle radiation of <sup>177</sup>Lu.
|
31399803 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
TTV on PSMA PET seems to be a reliable parameter for response assessment in mCRPC patients undergoing RLT and might overcome the limitations of RECIST in prostate cancer.
|
30569186 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combined Ga-PSMA-617 PET imaging and Lu-PSMA-617 therapy is a precise targeted theranostic approach for patients with metastatic castration-resistant prostate cancer (mCRPC).
|
30985422 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate-specific membrane antigen (PSMA) targeting alpha-radiation therapy (TAT) is an emerging treatment modality for metastatic castration-resistant prostate cancer.
|
31601699 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>177</sup>Lu-labeled prostate-specific membrane antigen (PSMA) radioligand therapy using PSMA-617 and PSMA-I&T ligands (<sup>177</sup>Lu-PRLT) is an emerging treatment in metastatic castration-resistant prostate cancer (mCRPC).
|
30683770 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Based on these promising preclinical results, <sup>152</sup>Tb was shipped to Zentralklinik Bad Berka, Germany, where it was used for labeling of PSMA-617, enabling PET imaging of a patient with mCRPC.
|
31346796 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients.
|
31587172 |
2019 |